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The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were
used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in
1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not
helpful for those with established psychotic disorders and should be avoided in those liable to develop
them. However, those with so-called ‘psychoneurotic’ disorders sometimes beneﬁted considerably from
their tendency to ‘loosen’ otherwise ﬁxed, maladaptive patterns of cognition and behaviour, particularly
when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal,
although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism
have both suggested efﬁcacy. The incidence of serious adverse events appears to be low. Since 2006,
there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilo-
cybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that
provide initial evidence of safety and efﬁcacy, however the regulatory and legal hurdles to licensing
psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre
and post prohibition, discusses the methodological challenges of performing good quality trials in this
area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a
treatment in mainstream psychiatry.
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The classical psychedelic drugs include mescaline, psilocybin,
dimethyltryptamine (DMT) and D-lysergic acid diethylamide (LSD).
Coined by psychiatrist Humphrey Osmond in a letter he wrote to
Aldous Huxley in 1956, the word ‘psychedelic’ is derived from the
ancient Greek words psyche (jycή, translated as “soul” or “mind”)
and delein (dhlεin, translated as “to reveal” or “to manifest”).
Therefore, psychedelic literally translates as ‘mind manifesting’ or
‘soul revealing’ (Osmond, 1957). Other terms such as ‘hallucinogen’
and ‘psychotomimetic’ are less favoured, perhaps because they
place too much emphasis on individual elements of a multi-faceted
subjective state.
Psychedelics were used long before the Western world was
introduced to them in 1897, when Arthur Heffter isolatedmescaline
from the peyote cactus. The earliest direct evidence for use of
psychotropic plants dates back 5700 years in the north eastern
region of Mexico (Bruhn et al., 2002), where carbon-dated buttons
of peyote cacti and red beans containing mescaline were found in
caves used for human habitation. The Eleusian ceremonies of
ancient Greece were likely based around some form of psychedelic
compound (Wasson et al., 2008). Psilocybin containing ‘magic’
mushrooms, which grow all over the world, appear to have been
used ubiquitously (Akers et al., 1992; Letcher, 2008). Mescaline is
still used in Native American Church ceremonies (Stewart, 1987). In
Brazil (McKenna et al., 1984) and the broader Amazonian basin
(Schultes and Hofmann, 1979), ritual healing practices and spiritual
ceremonies are practiced using ayahuasca, a drink which combines
plant derived DMT and b-carboline monoamine oxidase inhibitors
that allow it to be used orally.
The archetypal psychedelic inmodernWestern society, LSD, was
ﬁrst synthesised in 1938 by Albert Hofmann as part of a systematic
investigation of compounds derived from the ergot alkaloids at the
Sandoz laboratories in Switzerland (Hofmann, 2013). The ergot
alkaloids, which include lysergic acid and its derivatives, were
known to be responsible for episodes of mass poisoning in medi-
eval Europe from stocks of grain spoiled with the parasitic fungus
Claviceps Purpurea. In smaller doses, a speciﬁc ergot alkaloid
(ergometrine) was also known to be effective for treating bleeding
in women after childbirth due to its vaso- and utero-constrictive
properties. LSD was the 25th derivative of lysergic acid that Hof-
mann synthesised, explaining why it is sometimes referred to as
‘LSD-25’ (Hofmann, 2013).
In animal testing, LSD was found to be physiologically unre-
markable and the compound was shelved. Hofmann describes how
he decided to resynthesize LSD in 1943 on the basis of a ‘peculiar
presentiment … that this [compound] might possess properties
beyond those established in the ﬁrst pharmacological studies’
(Hofmann, 2013). On April 16th of that year Hofmann accidentally
contaminated himself with a small amount and, noticing somePlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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whereupon the full, and remarkably potent, effects of LSD on the
psyche became apparent for the ﬁrst time. Further investigation of
LSD by Sandoz found that, despite its potency, it was a notably non-
toxic compound physiologically. Recognising that its psychoactive
properties were likely to be of interest both to psychiatrists and
academics, it was marketed in 1947 under the trade name ‘Delysid’
and made freely available to those interested in researching its
properties. Hofmann also isolated and synthesised the active
component of psilocybe ‘magic’ mushrooms, psilocybin, in 1958
(Hofmann et al., 1959). This was marketed by Sandoz under the
brand name ‘Indocybin’.
At a time when psychiatry lacked effective medical therapies,
the discovery of LSD was of interest, with some key features noted.
Firstly, acute intoxication appeared tomimic some of the symptoms
of acute psychosis, particularly ego-dissolution, thought disorder
and visual misperceptions (although not, notably, auditory hallu-
cinations). Secondly, there appeared to be an increased awareness
of (and emotional connection to) repressed memories and other
elements of the subconscious, which was thought to be potentially
useful in those failing to make progress in psychotherapy. Physio-
logical toxicity was not observed, even after very large overdose.
However, initial testing of psychedelics in patients with schizo-
phrenia showed that they were not helpful, exacerbating psychotic
symptoms and failing to lead to clinical improvement. Trials in
depressive, anxious, obsessive and addictive disorders were more
encouraging, with the psychedelics noted to have therapeutic po-
tential within psychologically supportive contexts (Eisner and
Cohen, 1958) and a low risk of toxicity (Cohen, 1960). By the end
of the 1960s, hundreds of papers described the use of mescaline,
psilocybin and (most frequently) LSD in a wide variety of clinical
populations with non-psychotic mental health problems
(Grinspoon and Bakalar, 1981).
However, as the psychedelics diffused into wider society and
recreational use increased, some individuals reported a variety of
ongoing symptoms including visual distortions, ﬂashbacks and
other symptoms that occurred long after the drugs had left the
body. This came to be classiﬁed as ‘Hallucinogen Persisting
Perceptual Disorder’ (Halpern and Pope, 2003). Unethical and
covert use of psychedelics along with a general hardening of socio-
political attitudes towards drug use contributed to the decision to
place psychedelics in Schedule I of the 1967 UN Convention on
Drugs. Medical use ceased and research dwindled until the turn of
the millennium, since when there has been a steady renaissance of
clinical and academic interest in the psychedelic drugs, reﬂected by
a socio-political narrative that has increasingly questioned the
relative beneﬁts and harms of the so-called ‘war on drugs’ (Godlee
and Hurley, 2016; Hari, 2015).
This paper presents a synopsis of selected clinical studies with
psychedelics performed before 1970 and all major clinical studiessychedelic drugs. Past, present & future, Neuropharmacology (2017),
J.J.H. Rucker et al. / Neuropharmacology xxx (2017) 1e19 3since the turn of the millennium. We discuss the controversies and
practical considerations in designing modern clinical trials with
psychedelics and review the formidable legal and regulatory hur-
dles that must be overcome if psychedelics are to become licensed
medicines in psychiatry again.
2. Pre-prohibition clinical studies
2.1. 1895e1940. Studies with mescaline
The ﬁrst medical report of use of a classical psychedelic in
Western medicine was made by Prentiss and Morgan in the United
States in 1895, who reported the ceremonial use of buttons of the
peyote cactus by indigenous people in Central America (Prentiss
and Morgan, 1895). Mitchell, reporting in the British Medical
Journal in 1896, reports self-experimentation with peyote,
describing closed-eye visual experiences and commenting that ‘for
the psychologist this agent should have value’ (Mitchell, 1896). This
was a view repeated by Havelock Ellis in 1897, describing the
experience as ‘…mainly a saturnalia of the speciﬁc senses, and chieﬂy
an orgy of vision … it is of no little interest to the physiologist and
psychologist’ (Ellis, 1897).
Whilst Arthur Heffter isolated the active component of peyote
(mescaline) in 1897, there is limited further mention of it in the
English medical literature until 1913, when Alwyn Knauer admin-
istered mescaline by subcutaneous injection to himself and other
volunteering physicians (Knauer and Maloney, 1913). Knauer had
worked as an assistant to the psychiatrist Emil Kraeplin who, aside
from his involvement in the inception of psychiatric diagnosis, was
also interested in the effects of psychoactive drugs in producing
psychopathology. However, his experimentations were restricted,
according to Knauer, to ‘substances, which … produce mental states
which have little similarity to actual insanities’. Administering
mescaline repeatedly both to themselves and other volunteering
physicians, they commented, ‘Soon after the onset of the visual hy-
peresthesia, to nearly all the investigated persons, out of total dark-
ness, kaleidoscopic pictures appeared.’ Whilst commenting on the ‘
… vividness of the [visual] hallucinations… they came unsought, they
were uncontrollable … ’ they also noticed that ‘the independence of
the hallucinations to thought and will was never quite absolute. On
the nature of the conscious experience under mescaline, they noted
that it ‘ … remained practically unclouded … somewhat similar to …
consciousness in hypnosis’ (Knauer and Maloney, 1913). Whilst the
nature of hallucinations in psychosis remained opaque, Knauer and
Maloney recognised that the mental state induced by mescaline
bore some similarity to the psychotic state.
Heinrich Kluver, in 1926, again experimenting on himself,
commented, in addition to the established visual imagery, on
changes in ‘object-awareness’ and ‘self-awareness’ (referred to in
the original German ‘gegenstandsbewusstsein’ and ‘ichbewusstsein’):
‘My body and its organs seemed to be most of the time non-existent
or detached from me as a perfectly functioning machine. While
speaking I seemed to listen to a speech apparatus… In general, the
line of demarcation drawn between ‘object’ and ‘subject’ in normal
state seemed to be changed. The body, the ego, became ‘objective’ in
a certain way, and the objects became ‘subjective’. They became
subjective not only in the sense that they behaved as visionary
phenomena, but also in the sense that they gained certain affective
qualities … There is no doubt that these changes in ‘Gegenstands-
und Ichbewusstsein’ are comparable to those observed in schizo-
phrenia’. (Kluver, 1926)
In 1936, Erich Guttman, then working at The Maudsley Hospital
in London, United Kingdom, raised the possibility of a therapeuticPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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colleagues, gave the drug to an undisclosed number of ‘medical
students’, ‘undergraduates’, ‘normals’, ‘psychopathic patients’, ‘manic-
depressives’, ‘schizophrenics’, ‘depressives’, ‘morphinists’ and those
suffering from ‘derealisation’ and ‘depersonalisation’ phenomena
(Guttmann, 1936). Not publishing any sort of objective results, he
nonetheless made the ﬁrst observation of the potential therapeutic
utility of the mescaline-induced state in psychotherapy, noting:
‘There is reason to suppose that patients in such a state may be very
susceptible to psychotherapeutic inﬂuence … If it is so, the intoxi-
cation could be made use of as a sort of forced or concentrated
analysis’.
Similarly, he recognised the importance of the drug for psychi-
atrists attempting to understand …
‘… the complicated interplay of aetiological factors in the origin of
psychoses. Careful analysis of one intoxication like mescaline
promises a reliable basis for knowledge in the ﬁeld of toxic psy-
choses generally, and perhaps hints for the solution of the great
problem of psychiatry, that of schizophrenia.’2.2. 1940e1970. Studies in psychotic disorders
Perhaps because mescaline was never marketed (it was ﬁrst
synthesised by Ernst Spaff in 1919 and then manufactured by the
pharmaceutical company Merck as a research chemical), but
perhaps also because of the predominance of psychoanalytic theory
at the time, its use by psychiatrists was sporadic and infrequent. In
contrast, after Hofmann synthesised LSD in 1943, not only did
Sandoz provide it free of charge to psychiatrists, but it came at the
same time as the emerging idea that psychiatric states might have
biological, rather than psychological, aetiologies. Moreover, regu-
lation of the medical community, and of medical research, was
minimal. Growth of interest in LSD was rapid.
In 1950, Busch and Johnson (1950), working in Missouri, United
States, published one of the ﬁrst studies using LSD in patients. They
gave 21 patients, mostly hospitalised with schizophrenic or manic
episodes, LSD. They observed that all patients showed ‘increases in
activity’, particularly thosewithmania. Based on these observations
they gave LSD to a further 8 patients. 3 had diagnoses of catatonic
schizophrenia, 4 ‘psychoneurosis’ and 1 ‘psychosomatic’. Describing
the results narratively,
‘The effect… disturbed the barrier of repression and permitted a re-
examination of signiﬁcant experiences of the past, which some-
times were lived with frightening realism. With this, some of the
patients were then able to re-evaluate the emotional meaning of
some of their symptoms, and improved. Most were better able to
organize their ideas in relation to real rather than fancied problems
and were seen to experience and express relevant emotion. Two of
the patients [both psychoneurotic]… were improved sufﬁciently to
discontinue treatment … ’
In a further group of 59 individuals with schizophrenia divided
into 17with 'pseudoneurotic' schizophrenia, 26with 'undeteriorated'
schizophrenia and 16 with 'deteriorated' schizophrenia, Paul Hoch
and colleagues variously administered LSD and mescaline (Hoch
et al., 1952). Not recording any objective data, they commented
that the drugs ‘markedly aggravated’ the mental symptomatology of
the individuals they studied. Those with ‘deteriorated’ schizo-
phrenia showed ‘catatonic withdrawals’ in response to the drugs.sychedelic drugs. Past, present & future, Neuropharmacology (2017),
J.J.H. Rucker et al. / Neuropharmacology xxx (2017) 1e194Whilst noting the propensity of the drugs to uncover newmaterial,
the therapeutic value of the drugs in this patient group was
considerably doubted. This was echoed in studies by Liddell (Liddell
and Weil-Malherbe, 1953) and Pennes (Pennes, 1954), who
observed worsening in those with undeteriorated and deteriorated
forms of schizophrenia, but improvement in some with ‘pseudo-
neurotic’ forms of schizophrenia. ‘Pseudoneurotic schizophrenia’ is
an archaic term that included a multitude of depressive, anxious
and obsessive symptomatology. None of these reports include de-
tails of follow up.
Making some attempt at follow up, Herman Denber and Sydney
Merlis gave 500mg mescaline intravenously to 25 patients with
schizophrenia. Whilst 1 patient achieved ‘complete remission’ from
her symptoms (and was well at 1 year follow) and 3 patients
showed temporary remission of symptoms, psychotic symptoms
were either reactivated or worsened in the remainder (Denber and
Merlis, 1955). In another study published in 1957, Sidney Merlis
gave 24 patients with chronic schizophrenia between 500 and
750mg of mescaline and noted that 1 ‘improved sufﬁciently to be
discharged’, 7 ‘temporarily’ improved and in the remainder ‘no
change’ was noted (Merlis, 1957). Reporting of adverse events or
those that worsened with treatment was not included in the report.
He concluded that mescaline was not a clinically effective agent in
schizophrenia.
After the early 1960s, clinical studies of the use of LSD and
mescaline in psychosis rapidly diminished as it became clear that
the drugs exacerbated the symptoms of most and did not lead to
clinical improvement. However, the differences between the psy-
chosis characterised by schizophrenia and the state characterised
by LSD was still of interest. Langs, in 1968, published a detailed
questionnaire study comparing schizophrenic patients and healthy
controls who were randomly assigned to be given LSD or placebo
(Langs and Barr, 1968). They noted that those with schizophrenia
manifested ‘somatic and persecutory delusions and hallucinations
which qualitatively extended far beyond anything reported by our LSD
subjects’. Nonetheless, ‘‘paranoid schizophrenics’ responses resem-
bled those of LSD-25 subjects in regard to feelings of unreality, loss of
controls, changes in the meanings of experiences, and suspiciousness;
they did not, however, exhibit the body image changes and elation-
related effects found in many of the drug subjects.’ It was noted
that the hallucinatory element of the LSD experience tended to be
largely visual in nature, whereas in the schizophrenic state auditory
hallucinations predominated.
2.3. 1940e1970. Studies in neurotic disorders
Ronald Sandison, then working at the Powick Mental Hospital
near Worcester, United Kingdom, published a paper in 1954 in
which 36 patients with predominantly ‘psychoneurotic’ disorders
were treated with variable doses of LSD given over a variable in-
terval (usually weekly) in the context of psychotherapy (Sandison
et al., 1954). LSD dosage was started at 25mcg and then
increased until an ‘adequate’ reaction was observed. This paper
described the ‘psycholytic’ method of psychedelic psychotherapy:
using LSD within the context of psychotherapy to ‘loosen’ ego de-
fences and catalyse access to traumatic material. 27 out of 30 with
more classical neurotic and depressive disorders were reported to
have beneﬁted from the intervention, although this was a subjec-
tive judgementmade by the treating clinician. Therewas no control
group and no details of those patients who worsened with the
treatment.
Reporting an extension of their research in a publication in 1957,
Sandison reported 6 month follow up in 93 patients with ‘severe
neuroses’ (Sandison and Whitelaw, 1957). Of these 93 (of which 30
were also included in the original 1954 paper), 21 (22.6%) werePlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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‘moderately improved’ and 32 (34.4%) ‘not improved’. Again, there
were no objective measurements, no control group and no infor-
mation on those who worsened in this study.
Chandler and Hartman, working in California, published a work
in 1960 in which 110 patients with predominantly ‘psychoneurotic’
and ‘personality disorder/trait’ diagnoses were given a total of 690
psychotherapy sessions using LSD, usually given in gradually
escalating dosages between 50mcg and 150mcg (Chandler and
Hartman, 1960). They also commented on the therapeutic utility
of music in ‘… helping to bring out affectively charged memories and
fantasies’. Experiences under LSD were likened to ‘a waking dream’
with the aim of therapy ‘… to understand it in terms of its emotional
meaning rather than to worry about its objective validity.’ Of these
110 patients, 50 showed ‘considerable’, ‘marked’ or ‘outstanding’
improvement, 38 showed ‘some’ or ‘slight’ improvement and 22
showed ‘little or no change’ or were ‘slightly worse’. No patients
were judged to be ‘deﬁnitely worse’. No control group was
reported.
Attempting to provide a control group, Whitaker, working in
Australia, described the use of an average of 3.28 LSD psychother-
apy sessions in the treatment of 100 patients, comparing those
treated with LSD psychotherapy to a group of patients treated in
years previous to the study that were similar in terms of diagnosis
and duration of illness (Whitaker, 1964a, 1964b). Of the 100 pa-
tients, 49 had ‘psychoneuroses’, 27 ‘personality disorder’, 21 ‘sexual
disorders’ and 3 ‘residual schizophrenia’. Outcomes reported were
clinician and patient agreements of improvement, divided into
‘successful’, ‘borderline’ and ‘failure’. Of the 100 patients undergo-
ing LSD therapy, 47 were judged to be successful outcomes, 18
borderline and 35 failure. In the control group 12 were judged to be
successful, 30 borderline and 58 failures. The rate of success was
observed to be higher (75%) in those with the shortest duration of
illness (0e2 years) as compared to those with the longest (more
than 21 years), where only 37% were classed as successes. Of those
35 who were deemed as treatment failures, 19 ‘evaded’ ongoing
therapy after their ﬁrst LSD experience. None of the 3 residual
schizophrenics were judged to have improved, however ‘a suc-
cessful result was obtained in more than half the cases of anxiety state,
hypochondriasis, hysterical personality, antisocial character disorder,
anorexia nervosa and exhibitionism’. Outcome data was based on
subjective judgements and the results were not analysed
statistically.
Probably the largest studies of the therapeutic utility of psy-
chedelics in the pre-prohibition era were carried out at the Spring
Grove State Hospital and the Maryland Psychiatric Research Center,
both in Baltimore, Maryland, United States during the 1960s and
early 1970s. Reporting on a total of 243 patients with a variety of
non-psychotic psychiatric diagnoses that included anxiety and
depressive disorders, personality disturbances and alcohol addic-
tion, Charles Savage and colleagues also pointed out ‘the crucial
importance of non-drug variables as determinants of reactions to
chemical agents [which is] not conﬁned to the psychedelics … ’
(Savage et al., 1967). They administered LSD without the context of
formal psychotherapy. LSD at a dose of 200e300mcg was given,
with mescaline at a dose of 200e400mg given to potentiate the
effect in some patients. Emotional support and companionship was
provided by a male and female sitter, but with no attempt made at
interpretation of material. Follow up was the next day, then at 1, 2,
4, 8, and 12 weeks and ﬁnally at 6 months. A questionnaire was
then sent, retrospectively, to the ﬁrst 113 patients in the sample.
Ninety-three replied. 83% reported ‘lasting beneﬁt’ and this was
found to be ‘highly correlated (tetrachoric r¼ 0.91) with the report of
a greater awareness of an ultimate reality’. The claimed improve-
ment rate was 76% at one to three months post LSD, and 85% in thesychedelic drugs. Past, present & future, Neuropharmacology (2017),
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months. Clinician ratings of improvement were made in retrospect
by 4 raters, with improvement ratings divided into ‘worse’, ‘none’,
‘some’, ‘substantial’ and ‘marked’. Of 243 patients, 197 (81.1%) were
judged to have improved to some degree: 35.8% showing ‘some’
improvement, 26.3% showing ‘substantial’ improvement and 18.9%
showing ‘marked’ improvement. Of the remainder, 16.9% showed
no improvement and 2.1% were ‘worse’.
2.4. 1940e1970. Studies with alcoholism
Clinical studies using LSD in the treatment of alcoholism before
1970 beneﬁted from a more systematic approach than other dis-
orders, probably because drinking behaviour is easier to quantify
objectively. Several reasonable quality controlled studies were
undertaken, particularly during the latter 1960s, however initial
studies were usually uncontrolled. For example, Maclean and col-
leagues gave 61 alcoholics and 39 patients with other diagnoses
400e1,500mcg LSD on an undisclosed number of occasions,
following them up for up to 18 months (Maclean et al., 1961).
Whilst noting that, of the alcoholics, 30 were ‘much improved’, 16
were ‘improved’ and in 15 there was ‘no change’, there was no
comparison control group.
In another study that included a comparison group, Jensen gave
LSD to 58 alcoholics on an inpatient unit in Ontario, Canada,
comparing this to 35 alcoholics given group psychotherapy and 45
receiving ‘standard’ care from psychiatrists not connected to the
study (Jensen, 1962). By chi square analysis, they reported a sig-
niﬁcant difference in rates of abstinence between those given LSD
and those given group psychotherapy and standard care. However,
the control groups were not matched and the authors stated that
the group treated with LSD were composed of people who
remained in follow up, whereas the control groups included those
lost to follow up. The methods of statistical analysis, chi square
statistic and p value for signiﬁcance were also not stated.
More systematic studies were published after 1965, often with
non-signiﬁcant results. Smart et al., in 1966, reported the effect of a
single LSD experience under controlled conditions on the behav-
iour of 30 alcoholics who were either inpatients or outpatients in
Toronto, Canada (Smart et al., 1966). They were randomised to a
control group that received standard care including psychotherapy,
a group who received standard care plus a 60mg dose of ephedrine
sulphate (a drug chosen because it shares some similar subjective
effects to LSD but with no known efﬁcacy in alcoholism), and
standard care plus an 800mcg dose of LSD. Drug treatments were
administered on a psychiatric ward, with participants kept over-
night. Otherwise treatment was the same. Both participants and
therapists were blind to treatment allocation. Nonetheless, in 19
out of the 20 drug sessions, the therapists correctly guessed the
drug condition. Baseline and 6 month follow up alcohol usage data
was collected in all groups by a participant- and researcher-rated
questionnaire. Researchers following up participants at 6 months
were blind to treatment and analyses were completed prior to
blinding being broken. No signiﬁcant differences were observed
between the groups in terms of pragmatic measures of alcohol
misuse.
Hollister et al., working in 1969 at the Veterans Administration
Hospital in California, USA, reported the results of a controlled
comparison of 72 male inpatients with alcoholism randomised to a
single dose either of 600mcg LSD or 60mg of dextroamphetamine
(Hollister et al., 1969). Music and low lighting was provided and a
research assistant was available for reassurance, but no attempt at
psychotherapy was made. Baseline and follow up measurements of
drinking and associated social effects were recorded with a scale
designed and validated for the trial. Follow up data was collected atPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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ment and independent of the treatment programme. Of the 72
patients, 20 had dropped out at 2 month follow up (10 in each
group) and 27 had dropped out of follow up by 6 months (11 in the
LSD group and 16 in the dextroamphetamine group). In terms of
mean change of questionnaire scores, analysed by ANOVA, those in
the LSD group were signiﬁcantly improved over the dextroam-
phetamine group (F¼ 8.5, p< .01), however the difference was not
signiﬁcant at 6 month follow up. Those who dropped out did not
differ signiﬁcantly in baseline scores compared to those who did
not. At 12 month follow up, only 17 patients remained in the LSD
group and 12 in the dextroamphetamine group, and the authors
considered analysis of this group unproductive.
Ludwig et al., working at the Mendota State Hospital in Wis-
consin, USA, published in 1969 a study inwhich 176male inpatients
with alcoholism were randomly allocated to one of three LSD
treatments and a control condition (44 participants per group)
(Ludwig et al., 1969). All participants allocated to the LSD groups
received 3mcg per kg of body weight, with the treatments differing
by the nature of therapy offered during the LSD experience. One
group received LSD plus hypnosis plus psychotherapy, a second
group LSD plus psychotherapy and a third group LSD alone. The
fourth ‘control’ groupwere required to spend an equivalent amount
of time in the treatment room by themselves, but no intervention
was otherwise given. Therapists were not blind to treatment group.
Evaluation was with a variety of symptomatology, drinking
behaviour and social adjustment inventories taken at baseline then
immediately post-treatment and at 3, 6, 9 and 12 months after
treatment. Researchers collecting follow up data were blind to
treatment allocation. All groups showed consistent improvements
and no signiﬁcant difference was found between the LSD groups
and the control groups. A similar approach, and non-signiﬁcant
result, was found in two further controlled studies by Bowen
(Bowen et al., 1970) and Tomsovic (Tomsovic and Edwards, 1970),
with borderline signiﬁcant results found by Pahnke (Pahnke et al.,
1970).
Meta-analysing the previous 6 studies, Krebs and Johansen
found that LSD treatment was signiﬁcantly associated with main-
tained abstinence at 1e3 months (OR¼ 2.07 95% CI, 1.26e3.42;
p¼ .004), but by 6 months statistical signiﬁcance was lost (OR,1.42,
95% CI, 0.65e3.10, p¼ .38) (Krebs and Johansen, 2012).
3. Clinical trials prior to prohibition: discussion
Studies of the clinical utility of psychedelics published prior to
1970 were, like many studies of that time, methodologically sub-
optimal. A non-exhaustive list of the obvious problems includes the
following:
1. Treatment groups were inadequately and inconsistently deﬁned
2. Treatments were inconsistently applied amongst groups
3. Control groups were often absent
4. Attempts to blind study teams were usually absent
5. Outcome measures were not validated
6. Outcome data was inconsistently reported
7. Adverse outcomes were often not reported
8. Statistical analysis of results was often absent
9. Power calculations were not used to estimate sample sizes
needed to detect an effect
Nonetheless, the pre-prohibition research strongly suggested
that psychedelic drugs were not useful for those with established
psychotic disorders and should probably be avoided in those liable
to develop them. Worsening of psychotic symptomatology was
observed in most of those with pre-existing schizophrenia andsychedelic drugs. Past, present & future, Neuropharmacology (2017),
J.J.H. Rucker et al. / Neuropharmacology xxx (2017) 1e196whilst the occasional case was observed to recover, no trial re-
ported improvements that might not otherwise have been attrib-
utable to the passage of time.
Reports were more encouraging in trials with so-called ‘psy-
choneurotic’ disorders, a term which covers a wide variety of
anxious, obsessive and depressive states. We have systematically
reviewed trials in broadly deﬁned unipolar mood disorder in
another work, which showed that nearly 80% of participants in
these trials were judged to have ‘improved’ by their clinicians
(Rucker et al., 2016). The data was not of sufﬁcient quality to meta-
analyse and clinical improvement was usually a subjective judge-
ment, rarely based on objective or validated scales. Indeed, initial
trials were usually little more than case series reported by clinicians
who probably had positive expectations about treatment. Studies in
later years suggest more moderate preconceptions, but still re-
ported subjectively deﬁned efﬁcacy in many cases. However, in
controlled trials with alcoholism using quantitative measures of
alcohol use, borderline or non-signiﬁcant ﬁndings were often re-
ported. Given the lack of power calculations, this may reﬂect a lack
of power to detect an effect or a true lack of efﬁcacy. Krebs and
Johansen's meta-analysis of these studies suggests the former, at
least in the use of LSD in the treatment of alcohol dependent in-
dividuals (Krebs and Johansen, 2012).
Side effects, or adverse events, during the experience were
generally not reported systematically, if at all. Interpretation of an
adverse event's aetiology varied according to research team,
particularly for mental phenomena. This ranged from a directly
toxic action of the drug on the brain, which tended to cluster within
studies of those with schizophrenia, to the expected expression of
repressed trauma, which tended to cluster within studies of those
with neuroses and alcoholism. This may reﬂect both the varying
perspectives of cliniciansabout the aetiology of mental disorder and
the pharmacological effect of the drugs. We have listed reported
adverse events (non-exhaustively in view of space) in Table 1. Im-
mediate adverse events were more often reported than delayed
adverse events. In no particular order (frequencies were rarely re-
ported), headaches, palpitations, gastrointestinal disturbances,
changes in temperature perception, feelings of tremulousness or
dizziness, and a variety of other somatic complaints were most
commonly reported.
A consistent theme was a disparity between the degree of
subjectively reported physical symptoms and objective clinical
signs on medical examination, which tended to reveal only minor
increases in pulse rate and blood pressure along with pupillary
dilatation and, occasionally, signs of body temperature changes
(shivering and piloerection, or sweating). The signiﬁcance of this
disparity is uncertain, however may represent both an increased
subjective awareness of bodily sensations under the inﬂuence of
psychedelics, as well as drug induced changes in the autonomic
nervous system itself.
Sidney Cohen, in 1960, attempted to systematically investigate
the incidence of adverse events during treatment with psychedelics
by sending a questionnaire to 62 investigators who were using LSD
or mescaline in healthy subjects or patients (Cohen, 1960). 44 in-
vestigators replied. The data covered almost 5000 individuals given
LSD or mescaline on a total of more than 25,000 occasions. No
instance of physiological toxicity was reported. Of those with pre-
existing psychiatric problems receiving LSD or mescaline, the rate
of attempted suicide was 0.12%, completed suicide, 0.04% and
psychotic reactions lasting over 48 h, 0.18%. The rate in healthy
subjects was 0%, 0% and 0.08% respectively. No instance of addiction
was reported. The instances of these serious events appear rather
low and the study can be criticised for relying on the recall of cli-
nicians who may have underestimated (or been unaware of) the
nature and degree of adverse reactions in their subjects,Please cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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risk of experiencing them).
In a narrative report of nine cases who had suffered a variety of
persistent psychotic and neurotic symptoms after recreational use
of, or medical treatment with, LSD, Cohen and Ditman concluded
that complications were ‘much more likely to occur after the unsu-
pervised or inexpert use of the drug.’ Whilst the study was unsys-
tematic, themajority of cases occurred using illicit LSD takenwithin
a psychologically destabilising milieu that also included other
psychoactive drugs and lack of access to timely medical assistance
(Cohen and Ditman, 1963). This was a view echoed by Strassman in
a comprehensive review of adverse events to psychedelics in 1984
(Strassman, 1984).
As recreational use of LSD andmescaline increased in the 1960s,
so evidence of toxic psychological reactions in sensitive individuals
accumulated, with occasional tragic cases (Keeler and Reiﬂer, 1967)
accompanied by sensationalist media reporting. This paralleled
investigation of psychedelics as so-called ‘truth drugs’ or chemical
weapons, particularly by the Central Intelligence Agency (Lee and
Shlain, 2007). An immoral failure, these experiments (and the
public outcry over them) accompanied amore general hardening of
socio-political attitudes towards psychoactive drugs. Moreover,
unethical medical use of psychedelics probably occurred in some
centres. Whilst documentation is patchy, concerns about this issue
were reﬂected in a legal ruling in Denmark, where the ‘LSD Dam-
ages Law’ was enacted in 1986. This led to a series of 151 patients
gaining compensation in the 1980s and 1990s for a variety of psy-
chiatric symptomatology that was presumed (but not proven) to
have resulted from LSD treatment that was claimed sometimes to
have been given under coercion, or without informed consent
(Larsen, 2016). A critique of the report of these cases has recently
been published (Erritzoe and Richards, 2017).
In summary, the research conducted prior to 1970 suggests that
whilst there was certainly clinical interest in the therapeutic po-
tential of psychedelics in patient populations with non-psychotic
mental health problems, a ﬁrm conclusion about efﬁcacy and
safety was not reached prior to legal sanction that was largely
socio-political in motivation, although also reﬂected medical con-
cerns about the sequelae of recreational use. It is within this
agnosticism and strict regulatory framework that the modern
resurgence of research interest has taken place and to which we
now turn.
4. Modern clinical studies
In 1967, psychedelics, including mescaline, psilocybin and LSD,
were classiﬁed under Schedule I of the 1967 UN Convention on
Drugs. This legally deﬁned them as having no accepted medical use
and the maximum potential for harm and dependence. Successive
national legislation throughout theWesternworld tended to mimic
the 1967 UN Schedules. Medical use of psychedelics ceased quickly
because doctors were no longer permitted to prescribe them.
Without a clinical focus, research dwindled almost to a standstill in
the late 1980s and 1990s. This is depicted graphically in Fig. 1,
which shows the annual number of publications listed in the
database PubMed where the title refers to a classical psychedelic
drug, expressed as a proportion of all PubMed publications, from
1950 to 2016.
The herald to modern clinical research using psychedelics were
three papers investigating the effects of mescaline, dimethyltryp-
tamine and psilocybin in healthy volunteers by, respectively, Leo
Hermle et al. in Germany (Hermle et al., 1998), Rick Strassman et al.
in the United States (Strassman and Qualls, 1994), and Franz Vol-
lenweider et al. in Switzerland (Vollenweider, 1997). These studies
formed the basis for a resurgence of further studies in healthysychedelic drugs. Past, present & future, Neuropharmacology (2017),
Table 1
Summary of included studies, sorted by diagnostic category and year of publication. Lists of adverse events includes salient negatives. PR¼ pulse rate. BP¼ blood pressure.
Author(s) Year Predominant
Diagnosis
Sample
Population
Control
Population
Drug/Dosage Efﬁcacy Outcomes Adverse Events
(Immediate)
Adverse Events
(Delayed)
Maclean et al. 1961 Alcoholism 61 Alcoholism
11 Personality
disturbance
26 Neurosis
2 Psychosis
None LSD 400e1,500mcg Yes 52 'much
improved'
29 'improved'
19 'no change'
Frequency not stated.
'Transient nausea',
'mild headache', 'mild
gastric distress'.
Not reported
Jensen 1962 Alcoholism 58 Alcoholism 35
Alcoholism -
group
therapy
alone
45 controls -
'care’ from
other
psychiatrists
LSD 200mcg Yes Signiﬁcant
improvement in
rates of
abstinence for
alcoholics
receiving LSD
over those
receiving group
therapy or
standard care (chi
square)
Frequency not stated.
'Anxiety', 'nausea',
'tension', 'headaches',
'side effects … are
indicative of
emotional conﬂicts'
4/58 (6.9%)
treated with LSD
were lost to
follow up
18/35 (51.4%)
treated with
group therapy
alone were lost to
follow up
23/45 (51.1%)
treated by other
psychiatrists were
lost to follow up.
Smart et al. 1966 Alcoholism 10 alcoholism 10 þ 10
Alcoholism
10 - standard care
10 - standard care plus 60mg
ephedrine
10 - standard care plus 800mcg
LSD
No No signiﬁcant
difference
between groups
Not reported Not reported
Hollister et al. 1969 Alcoholism 36 alcoholism 32
alcoholism
32 - LSD 600mcg
32 - 60mg dextroamphetamine
Yes Superiority of
LSD at 2 months.
No signiﬁcant
differences at 6
months.
2 'nausea', 2
'vomiting', 2
'sufﬁciently agitated
to require IM admin.
of chlorpromazine
50mg', 1 'grand mal
seizure… in a patient
with previous history
of "rum ﬁts"', 1
'moderate confusion
requiring
hospitalisation for 4
days'
10 (LSD) vs 17
(D'amphetamine)
drop outs in each
group at 6 months
1 suicide (group
not stated)
Ludwig et al. 1969 Alcoholism 132 alcoholism 44
alcoholism
44 - standard care
44 - LSD 3mcg/kg
44 - LSD 3 mcg/
kg þ psychotherapy
44 - LSD 3 mcg/
kg þ psychotherapy þ hypnosis
No No signiﬁcant
difference
between groups
2 'LSD sessions had to
be terminated'
Not reported
Bogenschultz
et al.
2015 Alcoholism 10 Alcohol
dependence
None Psilocybin 300mcg/kg or
400mcg/kg
Yes Signiﬁcant effect
on the
percentage of
heavy drinking
days relative
baseline
Mild elevation of BP
1 vomiting, 1
diarrhea, 1 insomnia
1 dropped out
after ﬁrst
treatment
Osorio et al. 2015 Depression 6 Recurrent
depressive
disorder
None Ayahuasca 2.2ml/kg containing
0.8mg/ml DMT & 0.21mg/ml
harmine
Yes Signiﬁcant
reductions in
depressive
symptoms at 1
day, 1 week & 3
weeks.
3 vomiting.
Frequency not
reported: irritability,
decreased insight
Not reported
Carhart-
Harris et al.
(b)
2017 Depression 20 Treatment
resistant major
depressive
disorder
None Psilocybin 10mg & 25mg Yes Signiﬁcant effects
on self-rated
mood, maximal
at 5 weeks.
1 'patient became
uncommunicative'
during the drug effect
(duration not stated)
15 'transient anxiety
lasting for minutes'
5 'transient nausea'
3 'transient paranoia'
8 'headaches
lasting no longer
than 1e2 days'
No 'ﬂashbacks or
persisting
perceptual
changes'
5 'sought and
successfully
obtained
psilocybin
between 3 & 6
months [after
treatment]'
Sanches et al. 2016 Depression 17 Recurrent
depressive
disorder
None Ayahuasca 2.2ml/kg containing
0.8mg/ml DMT & 0.21mg/ml
harmine
Yes Signiﬁcant
reductions in
depressive
symptoms up to 3
47% vomiting Not reported
(continued on next page)
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Table 1 (continued )
Author(s) Year Predominant
Diagnosis
Sample
Population
Control
Population
Drug/Dosage Efﬁcacy Outcomes Adverse Events
(Immediate)
Adverse Events
(Delayed)
week study end
point.
Grob et al. 2011 Life
threatening
disease
12 Anxiety/
adjustment
disorder
secondary to an
advanced
cancer
diagnosis
Subjects act
as their own
control
(randomised
crossover)
Psilocybin 200mcg/kg &
Niacin 250mg (control)
No No signiﬁcant
difference
between groups
(positive trends
observed)
Mild elevation of HR
and diastolic BP
'No adverse
psychological
reactions from the
treatment'
Gasser et al. 2014 Life
threatening
disease
12 Anxiety
disorder
secondary to an
advanced
cancer
diagnosis
Unblinded
crossover
LSD 200mcg &
LSD 20mcg (control)
Yes Signiﬁcant
reductions in
state (not trait)
anxiety at 2
months,
sustained for 12
months
18 reports of adverse
events in LSD group
vs. 8 in active placebo
group
6 reports of mild
adverse events
persisting until
the next day
No 'lasting
psychotic or
perceptional
disorders'
Ross et al. 2016 Life
threatening
disease
29 Cancer
related anxiety
and depression
Blinded
crossover
Psilocybin 300mcg/kg & Niacin
250mg (control)
Yes Immediate,
substantial and
sustained clinical
beneﬁts
(statistically
signiﬁcant).
Variety of
outcome
measures.
Statistically
signiﬁcant increases
in BP/PR
28% 'headaches/
migraines'
14% 'nausea'
17% 'transient
anxiety'
7% 'transient
psychotic-like
symptoms'
No 'participants
abused or became
addicted to
psilocybin'
No 'cases of
prolonged
psychosis or
hallucinogen
persisting
perception
disorder'
No 'participants
required
psychiatric
hospitalisation'
Grifﬁths et al. 2016 Life
threatening
disease
51 Life
threatening
cancer with
anxiety and
depression
Blinded
crossover
Psilocybin 22mg/70 kg or 30mg/
70 kg &
Psilocybin 1mg/70 kg or 3mg/
70 kg
Yes Statistically
signiﬁcant
superiority of
high dose vs low
dose psilocybin
34% systolic
BP > 160mmHg (high
dose)
13% diastolic
BP > 100mmHg (high
dose)
15% 'nausea or
vomiting'
21% 'physical
discomfort (of any
type) (high dose)
32% 'psychological
discomfort (of any
type) (high dose)
26% 'anxiety' (high
dose)
1 'headache'
1 'transient paranoid
ideation' (high dose)
No 'cases of
hallucinogen
persisting
perception
disorder or
prolonged
psychosis'
2/11 'delayed
moderate
headache after
this high dose
session'
Sandison
et al.
1954 Neurosis 9 Obsessional
21 Depression/
Anxiety
4 Conversion
hysteria
2 Other
None LSD 25-400mcg over 2e40
weekly sessions
Yes 4/9 Obsessional
recovered/
improved
18/21
Depression/
anxiety
recovered/
improved
3/4 Conversion
hysteria
recovered/
improved
2/2 Other
recovered/
improved
Not reported Not reported
Sandison &
Whitelaw
1957 Neurosis 93
Predominantly
neurotic
(Includes 30
from 1954
paper)
None LSD 50-200mcg Yes 21 ‘recovered’
20 ‘greatly
improved’
20 ‘moderately
improved’
32 ‘not improved’
Suicidal ideation, self
harm, 'anxiety'
'Repetition of the
acute phase of the
experience days
or weeks after
treatment'
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Table 1 (continued )
Author(s) Year Predominant
Diagnosis
Sample
Population
Control
Population
Drug/Dosage Efﬁcacy Outcomes Adverse Events
(Immediate)
Adverse Events
(Delayed)
Chandler &
Hartman
1960 Neurosis 44
Psychoneurosis
36 Personality
disorder/trait
disturbance
22 Sociopathic
disorder
8
Miscellaneous/
Other
None LSD 50-150mcg Yes 4 'Outstanding
improvement'
20 'Marked
improvement'
26 'Considerable
improvement'
23 'Some
improvement'
15 'Slight
improvement'
19 'Little or no
change'
3 'Slightly worse'
0 'Deﬁnitely
worse'
Not reported 1 suicide
(previous history
of attempts). 1
transient
psychosis (1 day).
Whitaker (b) 1964 Neurosis 49
psychoneurosis
27 personality
disorder
21 sexual
disorder
3 residual
schizophrenia
100 patients
treated in
previous
years similar
in terms of
'diagnosis
and duration
of illness'
LSD 100-250mcg given 3.28
times on average. Total of 328
treatments given.
Yes LSD/Control
47/12 'successful
18/30 'borderline'
35/58 'failure'
No statistical
comparison
performed
Rescue medication
given in 14/328
(4.3%) of treatments
because of
'uncontrollable acting
out or intolerable
distress'.
'Several refused
further treatment
because they found
the experience too
distressing'
1/328 (0.3%)
'recurrence of the
LSD effect on the
following day'
'In about 1/3 of
cases there was
transient
increased distress
between sessions'
No instance of
delayed psychosis
No instance of
drug seeking
behaviour
Savage et al. 1967 Neurosis 63
psychoneurotic
2 schizophrenic
reaction
117 personality
disturbance
9 sexual
deviation
24 alcohol
addiction
27 other mostly
adjustment
reaction
None LSD 200-300 mcg þ Mescaline
200e400 mg 'if necessary' on
one occasion
Yes 46 'marked
improvement'
64 'substantial
improvement'
87 'some
improvement'
41 'no
improvement'
5 'worse'
Not reported 1 'manic attack …
treated
successfully with
psychotherapy'
1 'transient
psychotic episode
5 months after
LSD triggered by
an alcoholic
bender'
1 'claimed he had
been harmed
mentally'
Moreno et al. 2006 OCD 9 Obsessive
compulsive
disorder
None Psilocybin 25mcg/kg, 100mcg/
kg, 200mcg/kg & 300mcg/kg
No Signiﬁcant main
effect of time on
YBOCS scores. No
signiﬁcant effect
of dose.
1 transient
hypertension (mild)
2 dropped out after
session 1 'due to
discomfort with
hospitalisation'
Not reported
Busch &
Johnson
1950 Psychosis 20
Schizophrenia
3 Mania
4
Psychoneurosis
1
Psychosomatic
1 Paranoid state
None LSD. Dose not stated. Probably
between 20 and 60mcg
No Nil objective
results reported
'Improvement' in
2 psychoneurotic
patients
No improvement
in schizophrenia
patients
In order of frequency
(numbers not stated):
'Gastric distress',
'nausea & vomiting',
'muscle irritability',
'dizziness', 'pupil
dilation',
'hallucinatory ﬂashes
of light', 'chilliness',
'increase in pulse
rate', 'headache',
'ﬂushing of the skin'
Not reported
Hoch et al. 1951 Psychosis 17
Pseudoneurotic
schizophrenia
26
Undeteriorated
schizophrenia
16 Deteriorated
schizophrenia
None Mescaline 400e600mg
LSD 10-100mcg
No Nil objective
results reported
4 'mild'
deterioration
1 'marked'
deteriorating
1 'severe'
deterioration
'Catatonic
withdrawls' in
deteriorated
schizophrenia
group
Frequency not stated.
'Increased anxiety',
'hostility', 'paranoid
manifestations',
'visual
hallucinations',
'slurred speech',
'chilliness',
'headache',
'trembling', 'ﬂushing',
'numbness', 'sense of
heat', 'hyperacusis',
'pupillary dilatations',
Not reported
(continued on next page)
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Table 1 (continued )
Author(s) Year Predominant
Diagnosis
Sample
Population
Control
Population
Drug/Dosage Efﬁcacy Outcomes Adverse Events
(Immediate)
Adverse Events
(Delayed)
'nausea & vomiting',
'reinforces
schizophrenic
symptomatology &
magniﬁes it'.
Liddell &
Weil-
Malherbe
1953 Psychosis 3 Depression
4 Paranoid
schizophrenia
9 Other forms of
schizophrenia
2 Anxiety
hysteria
3 Psychopathic
states
None 25-60mcg LSD
40-60mg D-
methylamphetamine
No None objective
Worsening of
psychosis in
those with
schizophrenia
'Mood swings'
with
'predominant
euphoria' noted
with LSD
Frequency not stated.
'Flushing',
exacerbation of
schizophrenic
symptoms, 'mood
swings', 'shivering',
'piloerection',
'agitation', 'terror',
'worsening of
depression', somatic
complaints
Not reported
Pennes 1954 Psychosis 20
Pseudoneurotic
schizophrenia
25
Undeteriorated
schizophrenia
10 Deteriorated
schizophrenia
None Mescaline unknown dose
LSD 10-120mcg
No 'Normalisation'
reactions in 0%
'Intensiﬁcation'
reactions in 100%
given mescaline
and 64% with LSD
Frequency not stated.
'Anxiety & tension',
'hostility', 'paranoid
manifestations',
'depression',
'hypochondriasis',
'phobias', 'somatic
delusions', 'silliness',
'mannerisms',
'stereotypies',
'hysterical
manifestaiotns',
'inferiority feelings',
'catatonic
withdrawals'
Not reported
Denber &
Merlis
1955 Psychosis 25
Schizophrenia
None Mescaline 500mg IV No 1 'complete
remission'
3 'temporary
remission'
21 'psychosis
reactivated or
worsened'
Frequency not stated.
'Nausea', 'wretching',
'vomiting', 'sweating',
'palpitations', 'chest
& neck pains',
'dyspnea', 'anxiety',
'restlessness', 'panic',
'visual
hallucinations',
'auditory
hallcinations',
'paranoid delusions',
'somatic delusions',
'acute catatonic
withdrawal'
Not reported
Merlis 1957 Psychosis 24 Chronic
schizophrenia
None Mescaline 500e750mg No 1 'sufﬁcient
improvement for
discharge'
7 'temporarily
improved'
16 'no change'
7 'anxiety', 'increased
activity',
'intensiﬁcation of
hallucinations &
delusional thinking'
Not reported
Johnson et al. 2014 Tobacco
addiction
15 Tobacco
addiction
None Psilocybin 20mg/70 kg or
30mg/kg
Yes Signiﬁcant
reductions in
self-reported
daily smoking
from intake to 6-
month follow-up
10/42 (23.8%)
sessions included
strong or extreme
feelings of 'fear, fear
of insanity or feeling
trapped'
Mild increases in BP/
HR
8/10 participants
reported
transient, mild
post psilocybin
headache
responsive to
simple analgesia
No increases in
objective
bothersome
visual effects at 6
months
J.J.H. Rucker et al. / Neuropharmacology xxx (2017) 1e1910volunteers focussing on neuroimaging (Carhart-Harris et al., 2012,
2016b; Daumann et al., 2010; Muthukumaraswamy et al., 2013;
Palhano-Fontes et al., 2015; Preller et al., 2017; Riba et al., 2004,
2006; Vollenweider, 1997), psychopharmacological (Kometer et al.,
2012; Preller et al., 2017; Valle et al., 2016; Vollenweider et al., 1998)
and neuropsychological (Carter et al., 2007; Gouzoulis-MayfrankPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
https://doi.org/10.1016/j.neuropharm.2017.12.040et al., 2005) correlates of the psychedelic state. This literature is
beyond the scope of this clinically focussed review.
The ﬁrst modern clinical trial investigating the safety and
feasibility of using a psychedelic drug in a psychiatric patient
population was published by Francisco Moreno and colleagues,
working at the University of Arizona in the United States (Morenosychedelic drugs. Past, present & future, Neuropharmacology (2017),
Fig. 1. The effect of Schedule I on psychedelic drug research. Number of PubMed publications in which a classical psychedelic drug is found in the title expressed as a proportion of
all PubMed publications, by year, from 1950 to 2016.
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compulsive disorder and no other major psychiatric pathology
were given up to 4 different doses (25, 100, 200, 300mcg/kg body
weight) of psilocybin in an open-label design. Treatments were
separated by at least 1 week. 29 doses were given in total. The Yale
Brown Obsessive Compulsive Scale, the Hallucinogen Rating Scale
and a visual analogue scale measuring overall symptomatology was
administered at 0, 4, 8 and 24 h post dosing. Whilst signiﬁcant
reductions in OCD symptoms were observed in all dosing condi-
tions, there was no signiﬁcant difference between the different
dosages of psilocybin, although the trial was likely underpowered
to detect an effect. No serious adverse events were reported.
Matthew Johnson and colleagues, working at the Johns Hopkins
University inMaryland, United States, published an open-label pilot
trial in 2014 using moderate (20mg/70 kg) and high (30mg/70 kg)
doses of psilocybin given to 15 otherwise psychiatrically healthy
subjects with tobacco addiction undergoing a structured 15-week
smoking cessation treatment (Johnson et al., 2014). Psilocybin
was given at weeks 5, 7, and 13. Initial psilocybin dosing was with
the moderate dose and the higher dose offered, but not enforced, in
the subsequent sessions. A total of 19 meetings took place as part of
the smoking-cessation programme and psilocybin delivery. Bio-
logical markers of smoking cessation were assessed at baseline,
weekly throughout the treatment intervention and at 6 monthly
follow up. A total of 42 psilocybin sessions were delivered. No
clinically signiﬁcant adverse events were reported during the
treatment or follow up. 12 of 15 (80%) of participants were absti-
nent from tobacco as measured by biological markers at 6 month
follow up. Whilst this was highly signiﬁcant when pre and post
treatment self-reported smoking ﬁgures were comparedPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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given the open label design and low numbers of participants.
In a further open-label pilot study in 2015 on addiction, this
time to alcohol, Michael Bogenschultz and colleagues at the Uni-
versity of New Mexico, United States, gave psilocybin to 10 alcohol
dependent patients (4 women) in addition to standard motiva-
tional enhancement therapy (Bogenschutz et al., 2015). Psycho-
logical support was given before, during and after 2 psilocybin
sessions, spaced 4 weeks apart. The total treatment intervention
was 12 weeks. Outcome data was collected at baseline and for 36
weeks in total. The dose of psilocybin used was either 0.3mg/kg or
0.4mg/kg. The primary outcome was the percentage of days spent
drinking heavily compared between measures taken at baseline
and weeks 5e12. 9 participants completed follow up. Results sug-
gested, in linewith studies in the 1960s using LSD in alcoholics, that
the acute effects of psilocybin were less strong in this group. Large
and statistically signiﬁcant improvements in drinking behaviour
immediately after treatment were seen and these correlated with
the intensity of the drug effect. However, the open-label, uncon-
trolled design suggests caution is needed in extrapolating the
ﬁnding. No serious adverse events were noted. Again, the authors
concluded that psilocybin was a safe and feasible treatment to
deliver in a clinical trial setting.
Three pilot studies using psychedelics in major depressive dis-
order have been published to date in the modern literature
(Carhart-Harris et al., 2017, 2016a; Osorio et al., 2015; Sanches et al.,
2016). Our own open-label pilot study gave 2 doses of psilocybin (a
10mg “test” dose and a 25mg therapeutic dose) 1 week apart with
psychological support before and after the experience to 20 pa-
tients with treatment resistant depressionwhowere moderately tosychedelic drugs. Past, present & future, Neuropharmacology (2017),
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et al., 2017, 2016a). Participants were withdrawn from their anti-
depressant medications prior to psilocybin treatment. The primary
outcome measure was the mean change in the participant-rated
quick inventory of depressive symptoms rating scale from base-
line to 1 week after the second psilocybin treatment. Follow up was
for 6 months. No serious adverse events occurred. Signiﬁcant im-
provements in depression ratings were seen at 1, 2, 3 and 5 weeks,
and at 3 and 6 month follow up. The maximal effect was seen at 5
weeks (Cohen's d¼ 2.3). Further treatment seeking by participants
after 5 weeks, and particularly after 3 months, likely confounded
follow up data collected at 3 and 6 months. 5 of the 20 participants
sought and obtained psilocybin again during the follow up period.
The trial established feasibility in this patient group and initial
evidence of safety, but efﬁcacy interpretations are precluded by the
open-label, uncontrolled design.
Flavia de Lima Osorio and colleagues (Osorio et al., 2015) and
Rafael Sanches and colleagues (Sanches et al., 2016), both working
in Sao Paulo, Brazil, reported studies where a single dose of
ayahuasca to patients with recurrent depression. In Osorio's pilot
study, 6 medication and ayahuasca naive participants (4 women)
were given 2.2ml/kg of a standardised preparation of ayahuasca
containing 0.8mg/ml DMT and 0.21mg/ml of harmine. Measure-
ment of depressive symptoms was with the clinician rated Hamil-
ton Depression Rating Scale (HAMD) and the Montgomery Asperg
Depression Rating Scale (MADRAS). Baseline measurements were
compared with measurements taken at 1 day, 1 week, 2 weeks and
3 weeks after treatment. Signiﬁcant reductions in depressive
symptoms were seen at 1 day, 1 week, 3 weeks but not 2 weeks
after treatment, both with the HAMD and MADRAS. The treatment
was administered safely without any serious adverse events.
Sanches and colleagues conducted a follow up to this work with an
open-label study on 17 patients with recurrent depressive disorder
given the same dose of ayahuasca, with identical outcome mea-
sures. Again, signiﬁcant reductions in depressive symptoms were
observed up to the three-week end point of follow up. The treat-
ment was well tolerated with no serious adverse events. The failure
to collect participant rated scales of depressive symptoms and the
open-label design precludes clinical interpretation beyond feasi-
bility and safety.
Finally, four separate studies have been published on the use of
psychedelics in end-of-life anxiety associated with life threatening
illness (Gasser et al., 2014; Grifﬁths et al., 2016; Grob et al., 2011;
Ross et al., 2016). Charles Grob and colleagues, working in Califor-
nia, United States, gave 12 subjects (11 women) a moderate
(0.2mg/kg) dose of psilocybin and an active placebo (niacin
250mg) several weeks apart with psychological support in a
double-blind design in which subjects acted as their own control
(Grob et al., 2011). All subjects had advanced cancer diagnoses and
DSM-IV deﬁned acute stress disorder, generalised anxiety disorder,
or adjustment disorder with anxiety because of the cancer diag-
nosis. Four subjects were psychedelic naive. All 12 completed 3
month follow up. Non-statistically signiﬁcant trends towards im-
provements in mood were observed. The treatment was well
tolerated with no serious adverse events.
Peter Gasser and colleagues, working in Switzerland, gave LSD
to 12 patients with anxiety associated with life threatening disease
in a double-blind, randomised, active placebo controlled pilot trial
(Gasser et al., 2014) with a 12 month qualitative follow up study
also reported (Gasser et al., 2015). Drug free psychotherapy sessions
were supplemented by two LSD assisted psychotherapy sessions
given 2e3 weeks apart, in which participants were randomised to
receive either 200mcg or 20mcg of LSD. An open label extension
was offered to those randomised to the 20mcg dose. The State Trait
Anxiety Inventory was used as the outcome measure. SigniﬁcantPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
https://doi.org/10.1016/j.neuropharm.2017.12.040reductions were found in state, but not trait, anxiety at 2 months,
sustained at 12months. The treatment was delivered safely with no
serious adverse events. This is the only modern trial to our
knowledge that has used LSD in patients.
Two larger, double blind, randomised, placebo-controlled
crossover trials investigating the efﬁcacy of psilocybin in the
treatment of anxiety and depression in patients with life-
threatening cancer diagnoses were published from two separate
groups in the United States in 2016 (Grifﬁths et al., 2016; Ross et al.,
2016).
Working in New York University, Stephen Ross and colleagues
gave 29 patients a single dose of 0.3mg/kg psilocybin or 250mg
niacin, both in conjunctionwith psychotherapy. Crossover occurred
at seven weeks. 2 therapists worked with each patient and exten-
sive psychological support and therapy was provided. A variety of
clinician and participant rated measures, including the State Trait
Anxiety Inventory and the Beck Depression Inventory, served as
primary outcome measures and were collected at 1 day prior to the
ﬁrst dose, 1 day, 2 weeks, 6 weeks and 7 weeks after the ﬁrst dose,
then 1 day, 6 weeks and 26 weeks after dose 2. The treatment was
delivered safely, with no reports of serious adverse events. The
group receiving psilocybin showed ‘immediate, substantial, and
sustained’ clinical beneﬁts as measured by both clinician and
participant rated scales that lasted for the 7 weeks prior to cross-
over and were also sustained at the ﬁnal point of the study, 26
weeks after dose 2 (approximately 8 months after dosing). The
group that received niacin as dose 1 showed transient reductions
that were not sustained at 7 weeks. After crossover and receiving
psilocybin, immediate and sustained reductions in anxiety and
depression were observed, with the effect sustained at follow up at
6 and a half months.
Working in Baltimore, Roland Grifﬁths and colleagues gave
psilocybin using a similar double blind, randomised, crossover
design to 51 patients with life threatening cancer and associated
anxiety and depressive symptoms (Grifﬁths et al., 2016). In this
study, the placebo condition was a very low dose of psilocybin
(1mg or 3mg/70 kg) compared with a high treatment dose of psi-
locybin (22mg or 30mg/70 kg) administered in a counterbalanced
sequence with 5 weeks between sessions and 6 month follow up.
Thus, those who received the low dose of psilocybin ﬁrst received
the high dose second and vice versa. Extensive psychological sup-
port was provided before, during and after the experience and the
average length of participation in the study was approximately 9
months. The primary outcome measures were the Hamilton
Depression Rating Scale and the Hamilton Anxiety Scale, two
clinician-administered scales. The results showed statistically sig-
niﬁcant superiority of the high dose versus the low dose in terms of
the primary outcome measures and self-reported measures when
data at 5 weeks was considered. There were no serious adverse
events reported. Because participants crossed over from low to high
dose, and vice versa, at 5 weeks, the blind was effectively broken at
this point. Signiﬁcant associations between mystical type experi-
ences and enduring positive changes were observed, reﬂecting
previous research done by this group (Grifﬁths et al., 2008, 2006).
Commentary on both studies pointed out that the crossover
design and degree of psychotherapy provided around the psilocy-
bin experience may have confounded the effect attributed to psi-
locybin (Sellers and Leiderman, 2017). As ever, trials such as these
are often subject to the so-called ‘winner's curse’, whereby effect
sizes tend to be inﬂated in pioneering trials of new treatments due
to a variety of subtle effects. Future trials are likely to report more
modest ﬁndings.sychedelic drugs. Past, present & future, Neuropharmacology (2017),
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Clinical trials with investigational medicinal products (IMPs)
ultimately have one aim: to provide objective data to determine
whether the IMP in question is safe and efﬁcacious enough to
justify a license. In the modern context of research with classical
psychedelics, the IMP most likely to be licensed is psilocybin.
However, the legal, regulatory and commercial hurdles to this are
formidable. For the remainder of this article we concentrate on this
process and discuss, within the context of modern trials so far, a
strategic approach to tackling this challenge.
A license for an IMP results from approval from national medi-
cine's regulatory bodies. In the UK, for example, this is the Medi-
cines and Healthcare products Regulatory Agency. A license can be
gained via various ‘routes’. For example, existing drugs may be
relicensed with market exclusivity for rare diseases to drive
development in areas that would otherwise be commercially non-
viable (the ‘orphan’ drug route). However, most drugs are devel-
oped de-novo for more common diseases based on the commercial
potential predicated on a limited period of market exclusivity after
licensing. Regardless of the route, licensing is based on objective
data about the IMP's safety and efﬁcacy in deﬁned patient groups.
This requires a series of randomised, controlled trials (RCTs) con-
ducted on sufﬁcient numbers of participants in a regulated fashion
that seeks to collect valid, objective data about adverse outcomes
and to disambiguate the effects of the IMP from other inﬂuences on
outcome. A licensing decision is made based on a balanced judge-
ment of the risks and costs of treatment with the IMP weighed
against the risks and costs of the disease itself.
In the modern era, trials are divided into phases 1, 2, 3 and 4.
Phase 1 trials are open-label and investigate safety in small
numbers of healthy human volunteers. Phase 2 trials investigate
safety and feasibility in modest numbers of patients. Whilst pub-
lications that result from phase 2 trials often report data about
efﬁcacy they are actually more concerned with safety and feasi-
bility. They may be open label or controlled and the data is used to
design phase 3 trials, which are are usually RCTs that investigate
safety and efﬁcacy in larger numbers of patients. Data from phase 3
trials often form the mainstay of evidence used for licensing de-
cisions. Phase 4 trials are conducted on very large numbers of pa-
tients after a medicine has been approved and marketed and are
designed to pick up treatment effects and rare side effects that
could not reasonably be detected in phase 3 trials. At the time of
writing, psilocybin is undergoing phase 2 trials, with phase 3 trials
in the late stages of planning. This leads us naturally to a discussion
about the safety of psilocybin and the feasibility of the clinical trials
with it.
5.1. Safety
To date, 146 patients with a variety of psychiatric problems have
been treated with psilocybin and reported in the modern medical
literature. There have been no serious adverse events reported in
these trials, although the infrequent reports of drop outs suggest
absence of complete follow up data. A serious adverse event is
deﬁned as a reaction that results in death, is life threatening, results
in prolonged hospitalisation or persistent or signiﬁcant disability.
The absence of this so far is consistent with research using psilo-
cybin in healthy volunteers (Studerus et al., 2011), pre-prohibition
research with LSD and mescaline (Cohen, 1960), modern popula-
tion level data on recreational use of psilocybin mushrooms and
other psychedelics (Carhart-Harris and Nutt, 2013; Hendricks et al.,
2014, 2015; Johansen and Krebs, 2015; Krebs and Johansen, 2013a;
Nutt et al., 2010; Walsh et al., 2016) and toxicology work (Gable,Please cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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collecting adverse event data systematically in a manner that al-
lows aggregated analyses. The incidence of adverse events, and
particularly any cases of hallucinogen persisting perception disor-
der, mania, psychosis, self-harm or suicidal behaviour will need to
be compared between treatment and control groups, along with
assessments about causality. A single consolidated database of
adverse event information is necessary for regulatory approval. A
number of groups have recently collaborated in Europe to establish
this for trials using psilocybin in treatment resistant depression.
We have collated the most common immediate and delayed
adverse events reported in the literature in Table 1. Transient
anxiety, nausea, vomiting and mild increases in blood pressure and
heart rate are the most frequently observed immediate adverse
events. Headache is the most common delayed adverse event. No
cases of prolonged psychosis or hallucinogen persisting perception
disorder have been reported in modern trials with psilocybin,
ayahuasca or LSD. Dropout rates have been low, however in these
early trials participants may be a self-selecting group with
favourable attitudes towards psychedelics, which may be reﬂected
by the proportion reporting previous use. In our trial of psilocybin
in treatment resistant depression 35% of participants had a lifetime
history of psilocybin mushroom use. This is less than a recent
worldwide survey of 22,289 recreational drug users, which found a
lifetime prevalence of use of 43.1% (Winstock et al., 2013) but more
than prevalence ﬁgures of 17% for lifetime LSD, mescaline or psi-
locybin use amongst 21e64 year olds in the 2010 US National
Survey on Drug Use and Health (Krebs and Johansen, 2013b).
5.2. Dependence and diversion
There is very limited evidence that psychedelics cause depen-
dence or addiction (Brunton et al., 2011; Morgenstern et al., 1994).
Euphoria is not a consistent feature of the psychedelic experience,
tolerance develops quickly and completely and there is no known
withdrawal syndrome (Buckholtz et al., 1985; Cholden et al., 1955;
Isbell et al., 1956). Psychological dependence appears to be rare,
however research in this area is limited (Blacker et al., 1968). Thus
psychedelics appear to have a low potential for abuse relative to
other psychoactive drugs (Fabregas et al., 2010; Gable, 2007). Given
the above and the fact that psilocybin would be delivered within a
controlled healthcare setting rather than the community, the risk of
diversion of drug supplies in the context of existing security mea-
sures for other controlled drugs used in healthcare settings appears
to be low.
5.3. Feasibility and validity of RCTs with psychedelics
The ascendency of the RCT, which inherently attempts to
separate drug effects from their contexts, has its origins in the
Kefauver Harris Drug Amendments of 1962, which were developed
in response to the thalidomide tragedy. However, a common theme
in the literature is the opinion that psychedelics are therapeutic
within a psychologically supportive context, rather than thera-
peutic per se. Given the disparity between the mechanism of action
of psychedelics and the purpose of RCTs, some have argued that
RCTs with psychedelics are fundamentally ﬂawed and therefore not
feasible (Oram, 2012).
To exemplify, modern RCTs with psilocybin have shown large
effect sizes in distress associated with life threatening disease
(Grifﬁths et al., 2016; Ross et al., 2016), however in these studies the
psychological support provided was extensive. Criticism of these
trials reﬂects this (Sellers and Leiderman, 2017). At the other
extreme, Smart et al., in their 1966 study of LSD in alcoholism, tied
their participants to a bed with a Posey belt and gave them a verysychedelic drugs. Past, present & future, Neuropharmacology (2017),
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3-way interview about their alcohol use (Smart et al., 1966).
Perhaps unsurprisingly (the study was also probably underpow-
ered) negative results were reported. A meta-analysis of pre-
prohibition trials in alcoholism showed signiﬁcant evidence of ef-
ﬁcacy overall (Krebs and Johansen, 2012), however only one pilot
study has been completed so far in the modern era using psilocybin
in alcoholism. This found an encouraging effect on drinking
behaviour, however again psilocybin was given in the context of
quite extensive psychological support and a motivational
enhancement programme (Bogenschutz et al., 2015).
It appears that the problem of determining the relative contri-
bution of psychedelic and its context to the putative therapeutic
effect is difﬁcult. However, given that it would be unethical to give
psychedelics without some sort of psychological and emotional
support it seems germane to emphasise that this basic milieu is
(and morally must be) the treatment being tested. Thus, trials that
attempt to understand how different contexts interact favourably,
or unfavourably, with psychedelics may be of more value than
those that attempt to artiﬁcially separate them. At the same time,
the evidence for a licensing decision must include trials that focus
primarily on the drug itself.
Overall, whilst the RCT design is not ideal we conclude that
carefully designed clinical trials with psychedelics are feasible and,
since it would be unethical not to include a modest degree of
psychological support within the design, RCTs with this are, by
deﬁnition, valid. This has been demonstrated practically bymodern
pilot trials and RCTs with psychedelics, although the nature and
extent of psychological support provided will attract differing
opinions. We remain agnostic about outcome when the RCT design
is applied in phase 3 trials of psychedelics, but agnosticism is ul-
timately why the research is necessary.
5.4. Commercial viability
Phase 2 trials are relatively inexpensive in comparison to phase
3 trials, which often cost many millions of dollars and thus gener-
ally require proﬁt-driven commercial investment. This usually re-
quires the commercial potential inherent from a period of patented
market exclusivity for the developer. This allows recuperation of
development costs and generates income that drives further work.
However, since the patent on psilocybin (and LSD) has long expired,
commercial viability, at ﬁrst glance, seems doubtful. Treating psi-
locybin as an orphan drug is not an obvious solution to this because
the proposed disease areas (such as treatment resistant depression)
are not rare enough to fulﬁl criteria for this route. Trial costs are
exacerbated further by the security and bureaucratic requirements
imposed by Schedule I of the UN Convention on Drugs (Nutt et al.,
2013). How can phase 3 trials with psilocybin be funded if there is
no commercial potential to incentivise that funding?
The answer to this is multi-faceted. Recently, a UK based com-
pany announced a multi-center phase 3 trial of psilocybin in 300
patients with treatment resistant depression in Europe, with sig-
niﬁcant ﬁnancial backing from investors, suggesting that the
commercial potential does exist, at least in principle (“COMPASS -
Navigating Mental Health Pathways,” 2017). Grant holders in
Europe and the US have started to fund trials with Schedule I
substances over the last 10 years, perhaps reﬂecting a subtle shift in
socio-political attitudes. Psychedelics tend to capture the imagi-
nation of the public (as well as the media) and signiﬁcant sums
have been raised through social media-linked crowd funding as
well as from charitable and entrepreneurial sources (Emerson et al.,
2014; Nichols, 2014). So, whilst the commercial potential in psilo-
cybin may be somewhat atypically predicated, there is accumu-
lating evidence that it now exists in sufﬁcient quantity to fund thePlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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5.5. Schedule I
With commercial potential, the practical and bureaucratic bur-
dens imposed by Schedule I are inconvenient, but not insur-
mountable. Special licenses are required to process and administer
Schedule I drugs and strict security protocols are necessary that
require particular infrastructure. For example, pharmacies holding
Schedule I drugs in the UK must be monitored by closed circuit
television at all times and subject themselves to regular in-
spections. Storage containers holding Schedule I drugs must satisfy
certain security standards and be securely fastened to reinforced
walls or ﬂoors.
Those teams and institutions that have already conducted trials
with psilocybin have implemented these requirements and are
thus in a good position to conduct further research. With precedent
comes familiarity and then replication. As the socio-political
landscape changes, so do the attitudes of grant funders. In combi-
nation, this should stimulate other research groups to engage with
the practicalities of this ﬂedgling ﬁeld of research, where there is,
after all, plenty of room for expansion.
Moreover, there is historical precedent of Schedule I drugs being
developed for medical use. Dronabinol (synthetic delta-9-
tetrahydrocannabinol) was approved as an orphan drug for AIDS-
related anorexia in 1985 and is now also approved for cancer
chemotherapy related nausea and vomiting (Brafford May and
Glode, 2016). Xyrem (sodium g-hydroxybutyrate) was approved
for the treatment of cataplexy associated with narcolepsy in 2004
(Owen, 2008). An extract of cannabis sativa (nabiximols) was
licensed in 2010 in the UK for spasticity in Multiple Sclerosis
(Lakhan and Rowland, 2009). Extracts of cannabis are also being
investigated for certain forms of childhood epilepsy (Hussain et al.,
2015). Generally, the drug development pipeline is similar and a
successful licensing application results in the speciﬁc formulation
of the drug being legally rescheduled. At this point, the drug be-
comes prescribable by medical doctors without the need for a
special license, breaking the ‘vicious cycle’ of Schedule I research
suppression (Nutt et al., 2013). With the force of commercial in-
terest behind it, we anticipate a similar process for psilocybin if
efﬁcacy and safety are conﬁrmed.
5.6. Patient groups
If trials using psychedelics are commercially and legally viable,
thenwhich patient groups should be focussed on? In a costs-driven
world, it is likely that this will be those associated with high socio-
economic burden, morbidity and mortality and where effective
treatments are lacking or burdensome. Within psychiatry, the most
logical initial focus is probably unipolar depressive disorder, with
treatment resistant depression a priority. Unipolar depressive dis-
order is increasingly prevalent (Lopez and Murray, 1998; Murray
and Lopez, 1997; “World Health Organisation,” 2017), confers
startlingly high socio-economic burden (Greenberg et al., 2015,
1993; McCrone et al., 2008; van Wijngaarden et al., 2004; Wang
et al., 2003), is under-researched relative to disease burden,
related to poorer outcomes in a wide variety of physical health
problems (Moussavi et al., 2007) and is associated with a 20 fold
increased risk of completed suicide (Harris and Barraclough, 1997).
Of those who have a depressive episode, 85% will go on to have
another and successive episodes increase the risk still further
(Mueller et al., 1999). Treatment resistance, deﬁned as failure to
respond to at least two antidepressants, is common and longer
term, depth psychological and social therapies are sufﬁciently
expensive to deliver to make psilocybin therapy a viable potentialsychedelic drugs. Past, present & future, Neuropharmacology (2017),
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Whilst the initial focus of commercially driven trials is likely to
be treatment resistant depression, the largest modern trials to date
have been in psychological distress associated with terminal ill-
nesses. Clinical scenarios involving the use of psychedelics in
palliative care have inherent advantages in the process of gaining
regulatory approval, because the safety data requirements are not
as burdensome in groups where life expectancy is limited. None-
theless, evidence of efﬁcacy is still required and it is not yet clear
where the funding for phase 3 trials of psilocybin in end of life care
will come from.
Given the mechanism of action of psychedelics, the potential
scope of application could be wide. Functional neurological disor-
ders (Bryson et al., 2017) and anorexia nervosa appear interesting
candidates for further exploration, for example. However, it is
anathema to give psychedelics without informed consent, a point
that leads us into a ﬁnal brief discussion of the practical aspects of
conducting trials with psychedelics such as psilocybin.
5.7. Practical considerations in clinical trials with psychedelics
Whilst their physiological safety is relatively well established,
psychedelics elicit acute sensitivity to context and psychologically
toxic reactions do occur. Rarely, tragic circumstances have occurred
(Keeler and Reiﬂer, 1967; Reynolds and Jindrich, 1985), often
attracting disproportionate media coverage. In the light of this,
what practical steps can be taken to minimise risks in psychedelic
trials? A full discussion of this question has been covered elsewhere
(Johnson et al., 2008), but we present some key points, revolving
around our experience of using psilocybin in treatment resistant
depression.
5.7.1. Recruitment
Recruitment in trials of psychiatric disorders is inherently
difﬁcult as the disorders themselves affect motivation and adher-
ence. In addition to this more general problem, psychedelics are
stigmatised. This combination may lead to selection bias. This can
be overcome in part by using established clinical databases of pa-
tients that have consented to research contact, for example our own
at King's College London (Perera et al., 2009; Stewart et al., 2009).
This allows researchers to approach potential participants, rather
than relying on a self-selecting sample of volunteers contacting the
research team. On the other hand, self-selecting volunteers may be
less liable to experience adverse events to psychedelics because of
the positive preconceptions that motivate them to volunteer. Post
hoc comparisons of study samples with case registers can also help
determine to what extent study samples may differ to the pop-
ulations they are drawn from, as well as allowing comparisons with
‘treatment as usual’ cohorts.
5.7.2. Screening
Clinical trials with psychedelics should include adequate pro-
cedures to screen out high risk individuals. A personal or family
history of psychosis, personal history of mania, personal history of
repeated violence towards others and a recent personal history of
suicide attempt serious enough to require hospitalisation are sen-
sible exclusions, as is current drug or alcohol abuse (unless this is
the target for intervention). Medical screening should exclude
those with serious neurological, renal, liver or cardiac disease.
Given psilocybin's tendency to modestly increase blood pressure,
uncontrolled hypertension should also be an exclusion. Women
who are pregnant, at risk of becoming pregnant (inadequate
contraception) or breast feeding should also be excluded. All par-
ticipants should be registered with a local general or family prac-
titioner and consent to the sharing of their records with the studyPlease cite this article in press as: Rucker, J.J.H., et al., Psychiatry & the p
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motivations for participation.
5.7.3. Concomitant medications
Commonly prescribed psychiatric medications should be with-
drawn prior to use of psychedelics. Sufﬁcient washout time is
necessary, particularly for ﬂuoxetine (Burke et al., 2000). Some
tricyclic antidepressants, lithium, and the acute administration of
selective serotonergic reuptake inhibitors (SSRIs) may increase
sensitivity to psychedelics (Bonson and Murphy, 1996), as may
haloperidol (Vollenweider et al., 1998). Chronic administration of
SSRIs (Bonson, 1996; Stolz et al., 1983; Strassman, 1992) and
monoamine oxidase inhibitors (Bonson and Murphy, 1996) appear
to reduce sensitivity to psychedelics. Antagonists of the 5-HT2A
receptor (mirtazapine and most antipsychotic drugs) attenuate
response to psychedelics, as do benzodiazepines, particularly in
acute use. The effect of antiepileptic drugs is not known.
5.7.4. Psychiatric & psychological support
A psychiatrist with an appropriate Schedule I license is required
to prescribe and administer the psilocybin, manage other medica-
tion, medically monitor the treatment and provide assessment and
management of mental state and risk during the participant's
journey through the trial. At least one session of psychological
preparation is required for all participants and is probably most
effectively delivered by psychotherapists, psychologists or coun-
sellors that have experience of the psychedelic state and appro-
priate training (Phelps, 2017). Likely effects of the psychedelic
should be discussed and attention given to the possibility of long
forgotten, unknown or emotionally charged material surfacing.
On the day of the treatment, participants should be accompa-
nied at all times, preferably by those who provided psychological
preparation. Onset with psilocybin starts at about 30min, peaks
after about 90min and subsides after 4e6 h, making day case
treatment viable. A comfortable, supportive environment with easy
access to the lavatory is recommended. Music is often used to
accompany the experience and has been shown to enhance the
emotional response to psychedelics (Kaelen et al., 2015, 2016). A
psychiatrist should be available at short notice, but need not
necessarily be present.
Dysphoria, confusion, anxiety, agitation, panic and paranoia are
all expected reactions in a proportion of psychedelic experiences.
They are usually mild and respond to simple reassurance and
attendance to physical pain or discomfort. Rescuemedications are a
last resort, given under the supervision of the psychiatrist. A short-
acting benzodiazepine such as lorazepam or midazolam is recom-
mended. If rescue medications are used, it may be necessary to
arrange overnight stay and monitoring in the hospital or clinical
research facility. Otherwise, participants can leave the research
facility accompanied by a friend or relative once the clinical team is
satisﬁed that this is safe.
Follow up of participants should include at least one session of
psychological support with the therapist that has accompanied the
participant through the trial. The question of ‘howmuch is enough’
is difﬁcult. In a world where cost-efﬁciency is prioritised by most
healthcare providers and given the requirements of regulatory
bodies, we suggest that support should be minimal. We acknowl-
edge that some may strongly disagree with this idea, but believe it
strikes the right balance between idealism and pragmatism in the
context of clinical trials. The trial itself will be a support if it in-
cludes regular follow up for collection of outcome measure data
and psychiatric monitoring.
5.7.5. Blinding
In common with many trials of psychoactive drugs, effectivesychedelic drugs. Past, present & future, Neuropharmacology (2017),
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subjective effect is often obvious to participants and observers. This
creates expectancy effects in both trial participants and researchers
that can bias outcome measures and inﬂate effect sizes. This sug-
gests certain elements of trial design.
Firstly, ratings of primary outcomemeasures should be taken by
trained raters who are blind to treatment allocation and preferably
independent of the trial. Ratings should focus simply on the clinical
state over the time period required for the rating and should not
enquire about the nature and extent of the psychedelic experience.
Videos of such ratings allow quality control, comparisons between
raters and calculation of inter-rater reliability scores. Secondly,
active placebos should be considered. Active placebos can be sub-
threshold doses of the investigational drug or a different drug with
a similar (but non-therapeutic) psychoactive effect. Subthreshold
dosages of the investigational drug have the advantage of simplicity
and may be particularly effective if participants are not told the
different dosing regimens in a trial (although this approach may
raise ethical issues). However, subthreshold dosages may still be
psychoactive, potentially reducing statistical power and increasing
the likelihood of a type II error during analysis. Use of other psy-
choactive drugs as active placebos, such as methylphenidate, a
benzodiazepine, or niacin, has been performed. However, this in-
troduces the difﬁculty of choosing a drug that has a similar sub-
jective effect but is known not to have a therapeutic effect.
Crossover trials have been performed, but these are practically
difﬁcult and create problems with statistical analysis because of the
putatively extended therapeutic effect of psychedelics. There is
little consensus on which strategy is preferred.6. Conclusions
Psychedelics have a long history of use and yet they attract
emotive and often polarised opinions in modern Western society.
History suggests they may have a place in the treatment of re-
fractory neurotic disorders, particularly depressive disorder, anxi-
ety disorders, addictions and in the psychological challenges
associated with death and dying. Psychedelics appear to have a
context-dependent effect. This mandates carefully designed trials
within safe and comfortable settings staffed with psychotherapists
and psychiatrists familiar with their use.
Whilst modern pilot studies (largely using psilocybin) have
shown promise, treatments with classical psychedelics will need to
stand up to the scrutiny of the RCT design, which itself poses sig-
niﬁcant challenges. The money to ﬁnance RCTs with psychedelics
will likely come from a mixture of proﬁt-driven commercial en-
terprises, charitable organisations, crowd-funding and govern-
ment. The aim of RCTs is to demonstrate safety and efﬁcacy. If safety
and efﬁcacy is conﬁrmed, licensing and rescheduling will likely
follow. At this point, psychedelics will need to demonstrate deliv-
erability and cost-effectiveness if they are to become established
and accepted treatments. Many treatments fail these tests. Delivery
of psychedelics in real-world healthcare is likely to be expensive
relative to other interventions, underlining our opinion that they
are best investigated as options for those with socioeconomically
costly psychiatric problems (such as treatment resistant depres-
sion) that are refractory to cheaper and more established therapies.Author agreement/declaration
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